SMAD2 and colorectal cancer: Numerous studies have shown that miR‐486‐5p inhibits cancer, including prostate and colorectal cancers, through targeting specific genes.[79, 80] Liu et al.[81] revealed that miR‐486‐5p directly targets the 3′‐UTR of SMAD2, attenuating TGF‐β2‐induced SMAD2/3 phosphorylation in LECs (SRA01/04).